 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Research > Alizyme Therapeutics Ltd.
 |
Alizyme Therapeutics Ltd. |
 |
 |
 |
PROFILE |
 |
Alizyme is fighting the good fight against ills brought on by the good life. The development-stage biotechnology company licenses drug candidates and develops them; it targets conditions that are seen primarily in industrialized countries, including obesity, irritable bowel syndrome, inflammatory bowel disease, and Type II diabetes (often associated with obesity). Alizyme is focused on developing a family of lipase inhibitors, which prevent the body from absorbing fat. In addition to its pipeline of treatments for lifestyle-related conditions, the company is developing a drug for mucositis, cancer therapy-induced damage to the gastrointestinal tract.
COMPETITION |
 |
Ergo Science Corporation (ERGO)
GlaxoSmithKline plc (GSK)
Roche Group (ROHHY)
|
 |
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 0.00
KEY PEOPLE |
 |
Richard M. J. Palmer
CEO
Timothy P. McCarthy
CFO
CONTACT INFO |
 |
Granta Park, Great Abington,
Cambridge CB1 665, United Kingdom
Phone: 44-1223-896-000
Fax: 44-1223-896-001
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |